|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
AKT-forkhead box O3 signaling downstream of HTRA1 was activated via a tumor growth factor β signal, resulting in PRC death.
|
30273602 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present data may provide a contribution to future work directed at exploring the role of HtrA1 in tumor development and progression and at establishing whether it may be used as a promising tissue marker for some tumors.
|
29409460 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We aimed at identifying how HTRA1 in the vasculature affects tumor growth.
|
29713059 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HtrA1 staining was performed on tissue microarrays (TMA) comprised of tumor samples from a cohort of 106 women who were diagnosed with primary high-grade serous ovarian carcinoma and receiving standard treatment at the Québec University Hospital between 1993 and 2006.
|
30131069 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This manuscript reviews the current cancer-related HtrA1 research from the methodological and clinical standpoints including studies regarding its potential role as a tumor marker and/or prognostic factor.
|
26035313 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo studies, HtrA1 knockdown promoted tumorigenesis and conferred CDDP resistance in xenograft A549 tumors, which were reversed by intraperitoneal injection of LY294002.
|
24356998 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Indeed, HtrA1 over-expression caused a significant slowing down of tumor growth; moreover, cisplatin efficacy in reducing tumor mass was amplified by electroporation and this phenomenon was even more significant when combining the electroporation of cisplatin and HtrA1.
|
23747913 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HTRA1 downregulation was detected in more than 50% of the breast cancer specimens and was associated with higher tumor stage (p = 0.025).
|
23580433 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Emerging evidence has demonstrated that high-temperature requirement protein A1 (HtrA1) appears to be involved in several important biological processes in mammals such as growth, apoptosis, embryogenesis, invasion, metastasis, and cancer and has been verified to be reduced in a variety of human tumors.
|
23079781 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that HtrA1 is a downexpressed molecule since an early stage of bladder urothelial carcinoma development and that urinary HtrA1 protein may be considered, if successfully validated, as an early and highly sensitive and specific biomarker for this neoplasia (the sensitivity and specificity of HtrA1 are 92.65% and 95.59%, respectively).
|
23712470 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, these results suggest that HtrA1 may function as a tumor suppressor by controlling the epithelial-to-mesenchymal transition, and may function in chemotherapeutic responsiveness by mediating DNA damage response pathways.
|
22761798 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patients with tumors in early pathological stages (I-II) had significantly higher HtrA1 mRNA and protein expression levels than did patients with tumors in mid-to-late pathological stages (III-IV) (p < 0.05).
|
22935172 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analysis showed 57% (105/184) of primary EC tumors had low HtrA1 expression.
|
21098697 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of HtrA1 was more frequently found in tumors in Edmondson grade III-IV, especially in those with venous invasion, compared to tumors in Edmondson grade I-II.
|
20943460 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results showing downregulation of HtrA1 and HtrA3 gene expression support previous studies suggesting a tumor suppressor role for these genes.
|
19424634 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here we show that expression of HtrA1, which is frequently downregulated in ovarian cancer, influences tumor response to chemotherapy by modulating chemotherapy-induced cytotoxicity.
|
16767218 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations raise the possibility of HtrA1 as a candidate tumor suppressor involved in promoting serine-protease-mediated cell death and that downregulation of HtrA1 in ovarian cancer may contribute to malignant phenotype.
|
14716297 |
2004 |